Nanopartículas poliméricas funcionalizadas con dermatán sulfato para la distribución específica de compuestos bioactivos
The incidence of colorectal cancer (CRC) has increased among people under 40, attributed to lifestyle changes and the lack of preventive screenings. 5-Fluorouracil (5- FU) remains the standard treatment; however, its prolonged use is limited by the emergence of resistance, influenced by the presence...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | |
| Formato: | Tesis doctoral acceptedVersion |
| Lenguaje: | Español |
| Publicado: |
Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica
2024
|
| Materias: | |
| Acceso en línea: | http://repositoriouba.sisbi.uba.ar/gsdl/cgi-bin/library.cgi?a=d&c=posgraafa&cl=CL1&d=HWA_7852 https://repositoriouba.sisbi.uba.ar/gsdl/collect/posgraafa/index/assoc/HWA_7852.dir/7852.PDF |
| Aporte de: |
| Sumario: | The incidence of colorectal cancer (CRC) has increased among people under 40,
attributed to lifestyle changes and the lack of preventive screenings. 5-Fluorouracil (5-
FU) remains the standard treatment; however, its prolonged use is limited by the
emergence of resistance, influenced by the presence of cancer stem cells (CSCs) and the
activation of signaling pathways such as NF?B. The CD44 receptor plays a crucial role in
CRC, being considered a CSCs marker. This study aims to formulate nanoparticles (NPs)
of dermatan sulfate (DS) and chitosan, loaded with the anti-inflammatory tripeptide IRW
and 5-FU, to achieve their selective distribution. These formulations selectively interact
with tumor cells, CSCs, and endothelial cells (ECs) via DS and CD44. IRW loaded NPs
sensitize tumor cells to 5-FU treatment by inhibiting the NF?B pathway, increasing its
effectiveness, and selectively targeting injured ECs, reversing their activation.
Additionally, 5-FU NPs effectively deliver the drug to tumor cells, allowing the drug to
exert its antitumor function. In conclusion, this work presents an innovative approach
to improving CRC treatment, targeting both tumor cells and CSCs, offering new
strategies to address 5-FU tolerance and its side effects. |
|---|